Characteristics of Patients With Type 2 Diabetes Mellitus (CVD-RNDR)

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment

NCT05374343 ·Status: COMPLETED ·Phase: PHASE1

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

NCT03919656 ·Status: COMPLETED ·Phase: PHASE4

Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers

NCT07304726 ·Status: COMPLETED ·Phase: PHASE1

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

NCT02857764 ·Status: COMPLETED

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients

NCT05857085 ·Status: COMPLETED ·Phase: PHASE4

Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

NCT02610088 ·Status: COMPLETED ·Phase: PHASE4

Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers

NCT07304700 ·Status: COMPLETED ·Phase: PHASE1

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027 ·Status: COMPLETED ·Phase: PHASE1

Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)

NCT01948986 ·Status: COMPLETED ·Phase: PHASE1

A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus

NCT01574365 ·Status: TERMINATED ·Phase: PHASE2

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

NCT04203927 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

NCT05345327 ·Status: RECRUITING ·Phase: PHASE3

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

NCT05139914 ·Status: TERMINATED ·Phase: PHASE4

Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers

NCT07304687 ·Status: COMPLETED ·Phase: PHASE1

Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029

NCT05897216 ·Status: COMPLETED ·Phase: PHASE1

A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403

NCT01131091 ·Status: COMPLETED ·Phase: PHASE1

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF

NCT04739215 ·Status: UNKNOWN ·Phase: PHASE4

To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

NCT01069926 ·Status: COMPLETED ·Phase: PHASE1

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

NCT06828731 ·Status: COMPLETED ·Phase: PHASE1

Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

NCT05194592 ·Status: UNKNOWN ·Phase: PHASE4

Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin

NCT02899949 ·Status: COMPLETED

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620 ·Status: COMPLETED ·Phase: PHASE3

Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes

NCT03377335 ·Status: UNKNOWN ·Phase: PHASE4

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

NCT06204107 ·Status: COMPLETED ·Phase: PHASE1

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

NCT02317484 ·Status: COMPLETED